Literature DB >> 18056763

Non-canonical fibroblast growth factor signalling in angiogenesis.

Masahiro Murakami1, Arye Elfenbein, Michael Simons.   

Abstract

Whereas fibroblast growth factors (FGFs) classically transmit their signals via high-affinity tyrosine kinase receptors (FGFR1-4), recent evidence strongly implicates non-tyrosine kinase receptors (NTKR) or cell-surface FGFR-interacting proteins as important players in FGF signalling. Although NTKR have lower affinity for FGFs in comparison with cognate tyrosine kinase receptors, because of their high abundance they can effectively bind FGFs and produce unique biological effects independent of FGFRs. A prime example of such NTKR is the syndecan family of plasma membrane proteoglycans and, in particular, syndecan-4, which transmits FGF signalling via a protein kinase Calpha pathway. Another NTKR, alpha(v)beta(3) integrin, functions as an FGF signalling modulator by binding both FGF2 and FGFR1. Yet another NTKR, neural cell adhesion molecule (NCAM), can serve as an FGFR ligand and assemble an FGFR signalling complex in the absence of FGFs. Furthermore, N-cadherin, which has been reported to associate with FGFR, appears to activate FGFR in both ligand (FGF)-dependent and ligand-independent manners. Finally, gangliosides are implicated as a co-receptor system of FGFs. The biological consequence of non-canonical FGF signalling tends to be less discernable compared to the canonical FGFR activation because of the overlap between these two pathways; nevertheless, non-canonical signalling is important and sometimes essential for cellular functions. Given the diversity of FGF activities through embryonic development to adult physiology, the existence of the non-canonical signalling system may account for the different cellular response to the FGF input in different biological contexts. In this review, we will discuss recent findings related to non-canonical FGF signalling with emphasis on the endothelial biology and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056763     DOI: 10.1093/cvr/cvm086

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  36 in total

Review 1.  The extracellular matrix at a glance.

Authors:  Christian Frantz; Kathleen M Stewart; Valerie M Weaver
Journal:  J Cell Sci       Date:  2010-12-15       Impact factor: 5.285

Review 2.  Fibroblast growth factor signaling in the vasculature.

Authors:  Xuehui Yang; Lucy Liaw; Igor Prudovsky; Peter C Brooks; Calvin Vary; Leif Oxburgh; Robert Friesel
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 3.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

Review 4.  Targeting angiogenesis and the tumor microenvironment.

Authors:  Jennifer Samples; Monte Willis; Nancy Klauber-Demore
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

5.  Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766.

Authors:  Li Zou; Sheng Cao; Ningling Kang; Robert C Huebert; Vijay H Shah
Journal:  J Biol Chem       Date:  2012-01-14       Impact factor: 5.157

Review 6.  Endothelial Metabolic Control of Lymphangiogenesis.

Authors:  Pengchun Yu; Guosheng Wu; Heon-Woo Lee; Michael Simons
Journal:  Bioessays       Date:  2018-05-11       Impact factor: 4.345

7.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 8.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

9.  Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway.

Authors:  Arye Elfenbein; John M Rhodes; Julia Meller; Martin A Schwartz; Michiyuki Matsuda; Michael Simons
Journal:  J Cell Biol       Date:  2009-07-06       Impact factor: 10.539

10.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.